Pharmaceutical companies disclosed 2021 performance reports, a company's net profit increased by more than 30%

 With the arrival of 2022, pharmaceutical companies have recently begun to gradually disclose the performance reports of the previous year
.
Recently, Kelun Pharmaceutical's 2021 performance report was officially released
.
According to the data of the performance bulletin, the total operating income of Kelun Pharmaceuticals in 2021 will increase by 4.
64% from the previous year's 16.
464 billion yuan to 17.
229 billion yuan; the net profit attributable to shareholders of listed companies will increase by 32.
16% from the previous year's 839 million yuan, which is 1.
096 billion yuan; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses increased by 61.
54% year-on-year to 1.
015 billion yuan
.
Kelun Pharmaceutical stated that in 2021, the company will fully expand the market for infusion and non-infusion preparation products, and it will be effective; at the same time, the company's approved generic drugs in recent years have continued to increase volume, contributing a lot to operating income and net profit
.
In addition, the shareholding ratio of the subsidiary PATEO Biotech increased, and the loss of minority shareholders increased significantly year-on-year; at the same time, the company's operating scale expanded, and the corresponding management expenses such as salary and depreciation increased, which finally showed a change in operating performance
.
In addition, according to the announcement on January 12, the next-generation small-molecule STING agonist (KL340399 injection) developed by Sichuan Kelun Botai Biopharmaceutical Co.
, Ltd.
, a subsidiary of Kelun Pharmaceutical Holding Co.
, Ltd.
, was approved by the National Medical Products Administration (NMPA) for clinical trials.
Test notice
.
In addition to the official performance report released by Kelun Pharmaceuticals, many pharmaceutical companies have recently released performance forecasts for 2021.
According to the forecasts, many companies have positive performance forecasts
.
Such as Tigermed expects that the company's main business will continue to grow in 2021, and both operating income and net profit attributable to shareholders of listed companies will increase compared with the same period of the previous year
.
According to the forecast, Tigermed’s net profit attributable to shareholders of listed companies in 2021 is 2,624,662,200 yuan – 3,027,110,400 yuan, a year-on-year increase of 50%-73%
.
According to the 2021 annual performance forecast announced by Huaren Pharmaceutical, it is estimated that in 2021, its net profit attributable to shareholders of listed companies will be 125 million yuan to 150 million yuan, a year-on-year increase of 32.
10%-58.
52%; it is expected to achieve after deducting non-recurring gains and losses The net profit was 110-140 million yuan, a year-on-year increase of 23.
95%-57.
75%
.
Huaren Pharmaceutical said that the company has continuously integrated and improved sales channels, actively developed incremental markets, strengthened market access, and actively responded to the three-level centralized procurement policy at the national, provincial and prefectural levels, and drug sales increased compared with the same period last year
.
During the reporting period, the company actively promoted the layout of the entire medical and health industry chain, and the business of the pharmaceutical business segment grew steadily, contributing part of the profits
.
On the evening of January 12, Teyi Pharmaceutical also released a performance forecast.
It expects a net profit of 120 million to 150 million yuan in 2021, a year-on-year increase of 173.
87% to 242.
34%
.
During the reporting period, the company's business basically returned to normal levels, and sales revenue, especially the sales of the core product "Teyi" brand Zhikebao tablets, recovered well; at the same time, the company continued to strengthen brand building, optimize product structure, increase internal management, and adhere Cost reduction and efficiency enhancement achieved good results during the reporting period
.
In addition, Kaipu Bio predicts that the net profit attributable to shareholders of listed companies in 2021 is 800 million to 860 million yuan, a year-on-year increase of 120.
59% to 137.
14%; Dongbao Bio is expected to achieve a net profit of 30 million yuan attributable to shareholders of listed companies in 2021 -40 million yuan, a year-on-year increase of 62.
60%-116.
80%
.
Zuoli Pharmaceutical expects that the net profit attributable to shareholders of listed companies in 2021 will be 170 million yuan to 187 million yuan, an increase of 91.
44%-110.
58% over the same period of the previous year
.
Rejing Bio is expected to achieve a net profit of 2 billion to 2.
35 billion yuan in 2021, a year-on-year increase of 1684.
65% to 1996.
97%
.
2021 is a bumper year for China's pharmaceutical industry.
In addition to some companies' announcements of good results, according to the website of the State Drug Administration, as of December 30, 25 local innovative drugs have been "officially announced" in 2021.
Approved for listing, hitting a new high in the past three years
.
According to the industry, in 2022, the pharmaceutical industry will move towards maturity and rationality based on the improvement of the overall resilience
.